I agree. It's a riddle to all of us I fear. There are a
I agree. It's a riddle to all of us I fear. There are a lot of well-known names in the industry at NTEK and they can't help but see that something is not right. Here's the problem. They can't really go to Dave and say "Look, your brother is completely and utterly incompetent in this role. He's obviously not the man for the job. We need someone else in the CEO position as of yesterday." It's Dave's brother. They can't tell him that, no matter how much he needs to hear it. Maybe Dave can't tell Jeff that either. I don't know. It seems like a really stupid reason not to put a person in the position that can make them and us a lot of money by running the company with authority.
NTEK was run SO much better when Dave was in control. Make Jeff Chief Executive of Anything Else and put someone else in control. Why bother putting Jeff in a position he can't do? All of us understand that Jeff in the CEO position was purely ceremonial. Was the concern that PPS was going to nosedive if Dave was in control? I doubt it. I think we've been shown that PPS is hardly a concern to them, so why bother having Jeff in the CEO position when his skills have done nothing for the company? Things can only get better if they put someone else in place who can do the job. Dave managed to at least get NTEK to a point where the company looked good. Now... No new investors are going to invest in this company until they get their feet under them again, and Jeff does not have the capacity to do this. He's proven that time and time again.
I've said it a bunch of times now. I don't know Jeff as a person. He could be the nicest guy in the world, and I might even buy him a beer if we were hanging out. But, that would require me being able to afford beer and the PPS right now, I might have to get him a water instead. I am sure he's a great person in the right position. We all know this is not the right position for him.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
BioMarin's Latest Moves in Rare Disease Therapies Now here's a plot twist in the biotechnology landscape. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) just did what they do best—snagging rights to a promising enzyme therapy aimed at turning the tide for Fabry disease. In a deal that spoke volumes about their intentions, BioMarin is forking over a cool $70 million upfront...
Continue Reading
SCI's Rough Ride: Investors Brace for Impact There's nothing like waking up to find the stock you were banking on took a nosedive while you were dreaming of dividends. Service Corporation International (NYSE: SCI) sure gave shareholders more of a nightmare than a dream, slashing its earnings forecast for 2026 and watching its stock crumble by about 11.6% on October 29....
Continue Reading
Palmetto's New Release: Mergers & Acquisitions Focus Man, Palmetto Publishing just dropped a bombshell for home services aficionados with their latest M&A guide. Now, if you’re like me, swimming in stocks and always looking for that next big exit play, this one’s tailor-made for you. Mergers and acquisitions might not sound as flashy as the tech darlings or...
Continue Reading
Welcome to Fear Incarnated Ah, Kansas City. More than just jazz and barbeque. You’ve got these infamous haunted houses that turn every horror flick into a mere Saturday morning cartoon. Enter Edge of Hell and Beast Haunted Attraction. Two horrifying museums of fear that somehow lure us like flies to sugar from miles away. What's the secret sauce? Well, that’s half the...
Continue Reading
Crafting Stories with Precision: Cornue's Return In the world where Austin becomes a melting pot of ideas every spring, the return of David Cornue to SXSW casts a familiar, yet electrifying spark. This best-selling author and television whiz is slated to share his story magic at two workshops: one in the Lifestyle track and the other in the Film & TV track. Folks on-site...
Continue Reading
Folks, it’s a busy day on Wall Street, with Solink leading the charge by landing over a cool $100 million in fresh funding. Let's break this down because when startups pocket nine-digit figures, it's time to pay attention. Solink's Leap Forward Now, what’s Solink doing with all that cash? They're not scrambling for coffee money, that's for sure. Instead, this funding...
Continue Reading
Hanwha and Chainlink: A Game Changer in Tokenization What do Hanwha Investment & Securities, a heavyweight in Korea's finance scene, and Chainlink, the wizard of onchain finance, think they're up to? They're buddies now, locked and loaded, to tokenize real-world assets (RWAs). They're not just shaking hands; they're aiming to jiggle the global finance bedrock....
Continue Reading
Skechers Shareholders Stirring Over Lawsuit A fresh wave of legal antics is crashing at the shores of Skechers U.S.A., Inc. (NYSE: SKX) as frustrated shareholders mobilize against the footwear juggernaut. We're talking about a class action lawsuit here, folks, aimed at shaking down some clarity—or maybe just some cold, hard cash—from this bruiser over some sketchy...
Continue Reading
Strategic Financial Move for OPC Energy Here's the scoop from the powerhouse behind some major U.S. electricity moves: OPC Energy and its subsidiary CPV nailed down a hefty $825 million financing package for the Shore and Maryland power plants. This isn’t just any old financial shuffle. Nope, they've hammered out an all-in-one refinancing deal that's setting the stage...
Continue Reading
What's Cooking at wagamama with mamago? Here comes wagamama, striding into the American dining scene with that familiar bold Pan-Asian flair, now offering more than just a seat at their tables. The fresh move to a direct-to-door model dubbed ‘mamago’ ushers in an era where their signature dishes don't just seduce your taste buds at their restaurants. Nope, they are...
Continue Reading
Top 5 Most Recently Viewed Articles
United Community Banks, Inc. Declares Quarterly Cash Dividend United Community Banks, Inc. (NYSE: UCB) has made an exciting announcement regarding its preferred stock dividends, affirming its dedication to rewarding shareholders. The Board of Directors has approved a quarterly cash dividend set at $429.6875 per share. This translates to $0.4296875 for each depositary...
Continue Reading
Tempest Therapeutics Advances Amezalpat in Pivotal Trial Tempest Therapeutics, Inc. (Nasdaq: TPST) is thrilled to announce a major step forward in the fight against hepatocellular carcinoma (HCC), having received approval from China’s National Medical Products Administration (NMPA) to initiate a pivotal trial. This trial aims to evaluate the efficacy of amezalpat...
Continue Reading
Overview of the Hydrophilic Coating Market Growth The hydrophilic coating market is on a remarkable trajectory, with projections indicating a growth from USD 16.59 billion in 2023 to USD 27.23 billion by 2032, translating to a compound annual growth rate (CAGR) of 5.66% during this period. This surge is largely driven by advancements in biomedical technology and an...
Continue Reading
Counterweight Market Overview and Projected Growth The counterweight market is witnessing accelerated expansion, expected to reach approximately USD 6.1 billion by the year 2031. With a robust growth rate of around 4.9% during the forecast period, this sector is driven by the increasing demand across a wide range of applications. From elevators and forklifts to cranes and...
Continue Reading
VerticalScope Prepares for 2024 Financial Results Announcement VerticalScope Holdings Inc. (TSX: FORA; OTCQX: VFORF) is gearing up to unveil its fourth quarter and full year financial results for 2024. This announcement is eagerly awaited by investors and community members alike, as it reflects the company's performance and growth in the digital enthusiast platform space....
Continue Reading
